CMOs lacking GMP land snail-based OTC maker US FDA warning

By Dan Stanton contact

- Last updated on GMT

Snail mail? US FDA hits OTC maker with warning letter. GettyImages/Valengilda
Snail mail? US FDA hits OTC maker with warning letter. GettyImages/Valengilda

Related tags: Pharmaceutical drug, Food and drug administration, Fda

Failing to ensure third-party manufacturers operated in conformance with GMP has landed Korean OTC maker Seindni Co. Ltd a US FDA warning.

Inspectors from the US Food and Drug Administration (FDA) visited Seindni’s facility in Seoul, South Korea in May, and issued a Form 483 with several observations, to which the firm never responded.

In August, the FDA banned products made at the site from entering the US through Import Alert 66-40, and last week the Agency sent Seindi a warning letter highlighting violations of current good manufacturing practice (cGMP) regulations for finished pharmaceuticals at the plant.

“Your firm lacks an adequate quality unit,”​ the letter stated. You utilize contract manufacturers to manufacture your over the counter (OTC) drug products distributed to the United States. You explained to our investigator that you make finished product release decisions over the phone with your contract manufacturer, based on whether test results meet pre-established specifications.”

Seidni mostly makes snail-based cosmetic products. However, some of its products - specifically its skin protectant range - are classified as over-the-counter (OTC) sunscreen medicines by the FDA.

The letter added Seidni failed to have procedures covering the batch release process, and its quality unit lacked documentation to demonstrate acceptability of batch manufacturing and product quality.

Furthermore, the Agency said Seidni admitted during the inspection that its contract manufacturing organisations (CMOs) do not make its OTC products in conformance with cGMP.

“You have released some drugs for which neither you nor your contract manufacturers conducted release tests for identity and strength of active ingredients. As a result, some of your drugs are distributed without confirmation that they meet specifications for identity and strength of their active ingredients.”

Under section 501(a)(2)(B) of the Food, Drug, and Cosmetic Act (FD&C) Act, drugmakers are responsible for the quality of drugs they produce, regardless whether a third-party manufacturer is involved.

Related news

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers